Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: A hellenic cooperative oncology group study
dc.contributor.author | Briassoulis, E. Ch | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Bamias, A. T. | en |
dc.contributor.author | Dimopoulos, M. A. | en |
dc.contributor.author | Xiros, N. | en |
dc.contributor.author | Aravantinos, Gerasimos | en |
dc.contributor.author | Samantas, E. | en |
dc.contributor.author | Kalofonos, H. P. | en |
dc.contributor.author | Makatsoris, T. | en |
dc.contributor.author | Mylonakis, N. | en |
dc.contributor.author | Papakostas, P. | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Varthalitis, I. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Briassoulis, E. Ch | en |
dc.creator | Fountzilas, George | en |
dc.creator | Bamias, A. T. | en |
dc.creator | Dimopoulos, M. A. | en |
dc.creator | Xiros, N. | en |
dc.creator | Aravantinos, Gerasimos | en |
dc.creator | Samantas, E. | en |
dc.creator | Kalofonos, H. P. | en |
dc.creator | Makatsoris, T. | en |
dc.creator | Mylonakis, N. | en |
dc.creator | Papakostas, P. | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Varthalitis, I. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:52:35Z | |
dc.date.available | 2018-06-22T09:52:35Z | |
dc.date.issued | 2008 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41426 | |
dc.description.abstract | Background: Cancer of unknown primary (CUP) lacks established therapy although it affects 3% of cancer patients. We evaluated the irinotecan- oxaliplatin combination (IROX regimen) in previously untreated patients with non-favorable subsets of unknown primary carcinomas. Methods: This was a multicenter phase-II trial. Protocol treatment consisted of oxaliplatin 80 mg/m2 followed by irinotecan 160 mg/m2 administered every 3 weeks. The primary end points were response rate and toxicity, and secondary end points were time to progression and survival. Results: Forty-seven patients with liver, bone or multiple visceral metastases entered into the trial and received a median 6 chemotherapy cycles (1-11). The regimen was very well tolerated with one febrile neutropenia case and six cases with diarrhea grade 3 (16%). In intent-to-treat analysis the tumor response rate was 13% (95% CI = 4.8-25.7%) and 12 patients (27%, 95%CI 13.9-40.4%) had at least 4 months' duration of disease stabilization. The median time to progression was 2.7 months and the median survival was 9.5 months, with 40% of patients alive at 1 year. Conclusions: The IROX regimen demonstrated similar efficacy and a favorable toxicity profile compared to other more toxic chemotherapy combinations in patients with poor-prognosis CUP. © 2007 Springer-Verlag. | en |
dc.language.iso | eng | en |
dc.source | Cancer chemotherapy and pharmacology | en |
dc.subject | Article | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Adenocarcinoma | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Cancer growth | en |
dc.subject | Cancer survival | en |
dc.subject | Chemotherapy | en |
dc.subject | Priority journal | en |
dc.subject | Prognosis | en |
dc.subject | Abdominal pain | en |
dc.subject | Anemia | en |
dc.subject | Anorexia | en |
dc.subject | Antiemetic agent | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Constipation | en |
dc.subject | Diarrhea | en |
dc.subject | Disease-free survival | en |
dc.subject | Fatigue | en |
dc.subject | Febrile neutropenia | en |
dc.subject | Leukopenia | en |
dc.subject | Multicenter study | en |
dc.subject | Nausea and vomiting | en |
dc.subject | Neutropenia | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Antineoplastic activity | en |
dc.subject | Drug administration schedule | en |
dc.subject | Drug tolerability | en |
dc.subject | Fever | en |
dc.subject | Granulocyte colony stimulating factor | en |
dc.subject | Survival rate | en |
dc.subject | Bone metastasis | en |
dc.subject | Disease course | en |
dc.subject | Male | en |
dc.subject | Blood cell count | en |
dc.subject | Neurologic disease | en |
dc.subject | Clinical feature | en |
dc.subject | Organoplatinum compounds | en |
dc.subject | Side effect | en |
dc.subject | Atropine | en |
dc.subject | Camptothecin | en |
dc.subject | Irinotecan | en |
dc.subject | Loperamide | en |
dc.subject | Disease severity | en |
dc.subject | Liver metastasis | en |
dc.subject | Treatment response | en |
dc.subject | Weight reduction | en |
dc.subject | Multiple cycle treatment | en |
dc.subject | Drug withdrawal | en |
dc.subject | Liver disease | en |
dc.subject | Medical decision making | en |
dc.subject | Cancer of unknown primary site | en |
dc.subject | Cholinergic syndrome | en |
dc.subject | Combination chemotherapy | en |
dc.subject | Depression | en |
dc.subject | Drug activity | en |
dc.subject | Drug mechanism | en |
dc.subject | Oxaliplatin | en |
dc.subject | Peripheral neuropathy | en |
dc.subject | Phase-ii | en |
dc.subject | Trial | en |
dc.subject | Tumor localization | en |
dc.subject | Unknown primary | en |
dc.subject | Unknown-primary-carcinoma | en |
dc.subject | Visceral metastasis | en |
dc.title | Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: A hellenic cooperative oncology group study | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1007/s00280-007-0604-7 | |
dc.description.volume | 62 | |
dc.description.issue | 2 | |
dc.description.startingpage | 277 | |
dc.description.endingpage | 284 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Aravantinos, Gerasimos [0000-0002-2106-1713] | |
dc.contributor.orcid | Kalofonos, H. P. [0000-0002-3286-778X] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-2106-1713 | |
dc.gnosis.orcid | 0000-0002-3286-778X |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |